Treating Acute Covid-19—Final Chapters Still Unwritten
RT Gandhi, M Hirsch - New England Journal of Medicine, 2024 - Mass Medical Soc
Nirmatrelvir–ritonavir (Paxlovid [Pfizer]) is used as first-line therapy for nonhospitalized
persons with Covid-191 on the basis of the results of the Evaluation of Protease Inhibition for …
persons with Covid-191 on the basis of the results of the Evaluation of Protease Inhibition for …
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Objective To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …
[HTML][HTML] Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: a systematic review and network meta-analysis
J Jiang, Y Li, Q Jiang, Y Jiang, H Qin, Y Li - Journal of Infection, 2024 - Elsevier
Objectives This study aimed to determine the association of early use of oral antiviral drugs
(including nirmatrelvir-ritonavir and molnupiravir) with the risk of PCC and compare the …
(including nirmatrelvir-ritonavir and molnupiravir) with the risk of PCC and compare the …
Olgotrelvir as a single-agent treatment of nonhospitalized patients with Covid-19
R Jiang, B Han, W Xu, X Zhang, C Peng… - NEJM …, 2024 - evidence.nejm.org
Background Olgotrelvir is an oral antiviral with dual mechanisms of action targeting severe
acute respiratory syndrome coronavirus 2 main protease (ie, Mpro) and human cathepsin L …
acute respiratory syndrome coronavirus 2 main protease (ie, Mpro) and human cathepsin L …
Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation
L Yan, D Bui, Y Li, N Rajeevan… - Clinical Infectious …, 2024 - academic.oup.com
Background Nirmatrelvir-ritonavir is recommended for persons at risk for severe coronavirus
disease 2019 (COVID-19) but remains underutilized. Information on which eligible groups …
disease 2019 (COVID-19) but remains underutilized. Information on which eligible groups …
How To Measure Benefit in a Changing Pandemic—Olgotrelvir for SARS-CoV-2
AC Sherman, LR Baden - NEJM evidence, 2024 - evidence.nejm.org
Since January 2020, there have been over 775 million confirmed cases of Covid-19 and 7
million deaths globally. 1 Vaccinations and increased virologic exposure in the population …
million deaths globally. 1 Vaccinations and increased virologic exposure in the population …
Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform …
Background: Molnupiravir and nirmatrelvir-ritonavir (Paxlovid) are oral antivirals that have
been proposed as treatments for patients admitted to hospital with COVID-19. Methods: In …
been proposed as treatments for patients admitted to hospital with COVID-19. Methods: In …
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO …
I Gentile, A Giaccone, MM Scirocco, F Di Brizzi… - medRxiv, 2024 - medrxiv.org
Introduction Ritonavir-boosted nirmatrelvir (N/r) is an antiviral which targets the main viral
protease, administered to prevent the progression of SARS-CoV-2 infection in patients at …
protease, administered to prevent the progression of SARS-CoV-2 infection in patients at …
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial
Importance: The effect of montelukast in reducing symptom duration among outpatients with
mild to moderate coronavirus disease 2019 (COVID-19) is uncertain. Objective: To assess …
mild to moderate coronavirus disease 2019 (COVID-19) is uncertain. Objective: To assess …
[引用][C] Potential consequences of ineffective COVID-19 antiviral management.
HHT Ko - Academic Emergency Medicine: Official Journal of the …, 2024 - europepmc.org
Potential consequences of ineffective COVID-19 antiviral management. - Abstract - Europe
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …